Author details

Full Name

Adam J Bass

Affiliation

ORCID

Career Start Year

2002

Papers

135

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36525973	KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.	Cancer Cell	2023
36278961	Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer.	Clinical Cancer Research	2023
35365571	Adenocarcinoma of the oesophagus: is it gastric cancer?	Gut	2023
37794034	Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma.	Nat Commun	2023
37085570	Improving outcomes in patients with oesophageal cancer.	Nat Rev Clin Oncol	2023
36754726	Corrigendum to "Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma": [Annals of Oncology 33 (2022) 1134-1148].		2023
36752207	Developing SHP2-based combination therapy for KRAS-amplified cancer.		2023
36634297	Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.	JCO Precis Oncol	2023
36611031	Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers.	Nat Commun	2023
34969824	Transcription factor-mediated intestinal metaplasia and the role of a shadow enhancer.	Genes Dev	2022
35970241	Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective Cohorts.	Gastroenterology	2022
36329064	Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translation.	Nat Commun	2022
34571027	An Enhancer-Driven Stem Cell-Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer.	Gastroenterology	2022
34880227	A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer.	Nat Commun	2021
33972779	Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence.	Nat Genet	2021
33737385	Mutant p53 regulates Survivin to foster lung metastasis.	Genes Dev	2021
33506581	Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies.	Mol Oncol	2021
33505028	Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition.	Nature	2021
32709613	Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice.	Gut	2021
33403789	Rab11-FIP1 mediates epithelial-mesenchymal transition and invasion in esophageal cancer.	EMBO Reports	2021
34469333	Florid Foreign Body-type Giant Cell Response to Keratin Is Associated With Improved Overall Survival in Patients Receiving Preoperative Therapy for Esophageal Squamous Cell Carcinoma.	Am J Surg Pathol	2021
34508104	Inhibition of CK1Îµ potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.	Nature Communications	2021
34607954	heterozygosity and replication stress drive esophageal cancer development in a mouse model.	Proceedings of the National Academy of Sciences of the United States of America	2021
34716381	Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer.	Scientific Reports	2021
34377591	Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma.	Oncoimmunology	2021
34593617	Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.	Journal for ImmunoTherapy of Cancer	2021
31290142	Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.	Int J Cancer	2020
32142681	Hormonal Suppression of Stem Cells Inhibits Symmetric Cell Division and Gastric Tumorigenesis.	Cell Stem Cell	2020
32025000	Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model.	Nat Genet	2020
32294323	Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids.	Curr Protoc Stem Cell Biol	2020
32338747	Tumor Heterogeneity: Ignorance Is Not Bliss.	JAMA network open	2020
32209571	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy.	Clin Cancer Res	2020
33488961	Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor.	ACS Med Chem Lett	2020
33171128	Can Genomic Sequencing Identify High-Risk Barrett's Esophagus Earlier Than Pathologists?	Cancer Cell	2020
32999459	Repeat expansions confer WRN dependence in microsatellite-unstable cancers.	Nature	2020
31391338	Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma.	JCI insight	2019
31585941	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits.	Cancer Res	2019
31727671	Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.	Cancer Discovery	2019
29884612	Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.	Gut	2019
30971823	WRN helicase is a synthetic lethal target in microsatellite unstable cancers.	Nature	2019
30692993	Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?	Frontiers in Immunology	2018
28912017	Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and Is Associated With Type II Hypersensitivity/Autoimmunity.	Gastroenterology	2018
28978556	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.	Cancer Discov	2018
29054992	Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.	Cancer Discov	2018
30510992	Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells.	Cell Mol Gastroenterol Hepatol	2018
29976575	IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment.	Cancer Res	2018
30013197	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.	Nat Med	2018
30093730	Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.	Nat Med	2018
30087114	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung Cancer.	Cancer Immunol Res	2018
29574251	Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts.	Neoplasia	2018